JPRN-jRCT2080222571未知3 期
A phase III long-term study to evaluate the safety and efficacy of TAC-202 in patients with perennial or seasonal allergic rhinitis.
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Subjects who have been diagnosed with perennial allergic rhinitis and who have had related symptoms for 2 years or longer.
- •Subjects who have been diagnosed with seasonal allergic rhinitis and who have had related symptoms in Japanese ceder and Japanese cypress pollen season for 2 years or longer.
排除标准
- •Subjects who previously developed anaphylaxis to antihistamine drugs, or ingredients of the investigational drug.
- •Subjects with any of the following complications that may hinder efficacy evaluation.
- •- Vasomotor rhinitis
- •- Eosinophilic rhinitis
- •- Drug-induced rhinitis
- •- Viral conjunctivitis
- •- Otitis media
- •- Others (acute or chronic rhinitis, hypertrophic rhinitis, sinusitis, nasal polyps, repetitive nasal hemorrhage, treatment-requiring nasal septal deviation, etc.)
研究者
相似试验
未知
3 期
A phase III study of TAC-202 in patients with chronic idiopathic urticaria and pruritus accompanied by skin diseasesPatients with Chronic idiopathic urticaria, Eczema/Dermatitis, Prurigo, and Cutaneous pruritusJPRN-jRCT2080222478Taiho Pharmaceutical Co., Ltd.170
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-GBAlkermes Inc500
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-IEAlkermes Inc500
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-ATAlkermes Inc500
进行中（未招募）
1 期
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-BGAlkermes Inc500